Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Pharmacy
Published in: International Journal of Clinical Pharmacy 2/2013

01-04-2013 | Case Report

Famciclovir as an antiviral agent for a patient with acute renal failure

Authors: Hyonok Yoon, Ki Yon Rhew

Published in: International Journal of Clinical Pharmacy | Issue 2/2013

Login to get access

Abstract

Case Acyclovir is a widely administered medication for viral infection but is well known for its nephrotoxicity. To date, few studies regarding the safety of alternative antiviral agents have been reported. This study reports the case of a patient with renal dysfunction who suffers from acute herpes zoster (shingles) on her back. While renal function deteriorated with the use of acyclovir, the patient’s symptoms improved and baseline renal function recovered when she was treated with famciclovir. Conclusions Famciclovir could be taken as a first-line antiviral agent for patients with acute renal failure.
Literature
1.
Sacks SL. The role of oral acyclovir in the management of genital herpes simplex. CMAJ. 1987;136(7):701–7.PubMed
2.
Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med. 1982;73(1A):182–5.PubMedCrossRef
3.
Sawyer MH, Webb DE, Balow JE, Straus SE. Acyclovir-induced renal failure. Clinical course and histology. Am J Med. 1988;84(6):1067–71.PubMedCrossRef
4.
Fletcher C, Bean B. Evaluation of oral acyclovir therapy. Drug Intell Clin Pharm. 1985;19(7–8):518–24.PubMed
5.
6.
Htwe TH, Bergman S, Koirala J. Famciclovir substitution for patients with acyclovir-associated renal toxicity. J Infect. 2008;57(3):266–8.PubMedCrossRef
7.
Yavuz BB, Cankurtaran M, Halil M, Dagli N, Kirkpantur A. Renal dysfunction after oral acyclovir treatment in a geriatric woman: a case report. Scand J Infect Dis. 2005;37(8):611–3.PubMed
8.
Sodhi PK, Ratan SK. A case of chronic renal dysfunction following treatment with oral acyclovir. Scand J Infect Dis. 2003;35(10):770–2.PubMedCrossRef
9.
Johnson GL, Limon L, Trikha G, Wall H. Acute renal failure and neurotoxicity following oral acyclovir. Ann Pharmacother. 1994;28(4):460–3.PubMed
10.
Niibori D, Fujisawa M, Matsuzaki M. Severe central nervous system symptoms following oral administration of acyclovir in a patient with chronic renal failure: a case report. Hinyokika Kiyo. 1993;39(5):459–61.PubMed
Metadata
Title
Famciclovir as an antiviral agent for a patient with acute renal failure
Authors
Hyonok Yoon
Ki Yon Rhew
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9737-9

Other articles of this Issue 2/2013

International Journal of Clinical Pharmacy 2/2013 Go to the issue

Research Article

Patient perspectives on type 2 diabetes and medicine use during Ramadan among Pakistanis in Denmark

Research Article

Non-medical prescribers and pharmacovigilance: participation, competence and future needs

Research Article

A medication assessment tool to evaluate adherence to medication guideline in asthmatic children

Research Article

Community pharmacists in Khartoum State, Sudan: their current roles and perspectives on pharmaceutical care implementation

Research Article

Risk analysis and user satisfaction after implementation of computerized physician order entry in Dutch hospitals

Research Article

Impact of an intervention to reduce medication regimen complexity for older hospital inpatients
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits